CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC

MLA

Garon, Edward B., et al. “CheckMate 384: Phase IIIb/IV Trial of Nivolumab (Nivo) 480 Mg Q4W versus 240 Mg Q2W after ≤ 12 Months of Nivo in Previously Treated Advanced NSCLC.” Journal of Clinical Oncology, 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1343978893&authtype=sso&custid=ns315887.

APA

Garon, E. B., Reinmuth, N., Falchero, L., Garcia Garcia, Y., Hureaux, J., Gore, I., Harris, R. P., Bidoli, P., Baldini, E., Ros, S., Laack, E., Mitchell, P., Wolf, M., O’byrne, K. J., Zibdawi, L., Jao, K., Spigel, D., Li, A., Rabindran, S. K., & Pichon, E. (2019). CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC. Journal of Clinical Oncology.

Chicago

Garon, Edward B., Niels Reinmuth, Lionel Falchero, Yolanda Garcia Garcia, José Hureaux, Ira Gore, Ronald P. Harris, et al. 2019. “CheckMate 384: Phase IIIb/IV Trial of Nivolumab (Nivo) 480 Mg Q4W versus 240 Mg Q2W after ≤ 12 Months of Nivo in Previously Treated Advanced NSCLC.” Journal of Clinical Oncology. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1343978893&authtype=sso&custid=ns315887.